Cough analysis patent granted in China

Brisbane, Australia, 1 February 2022 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that the China National Intellectual Property Administration has accepted for grant the company's patent application 201910202125.5 titled, "A method and apparatus for processing patient sounds."

This patent covers the use of a cough sound-based audio processing pipeline for diagnosing respiratory disease. The patent is owned by The University of Queensland and is licensed exclusively to ResApp for the lifetime of the patent. The inventors are Dr Udantha Abeyratne, Dr Vinayak Swarnkar and Dr Yusuf Amrulloh. This pivotal patent family has also been granted in Australia, Japan, Korea and the United States of America, and is pending in Europe.

CEO and Managing Director, Dr Tony Keating said: *"Receiving this patent grant for our core technology is a key step in our market entry plans for China. China presents multiple large market opportunities for ResApp's products. According to UBS, the Chinese telehealth market is expected to reach US$54B by 2025, and there is a critical need for triage tools in China's overburdened hospitals. China also has over 45 million people with asthma and 100 million people with COPD, which brings large opportunities in chronic disease management. Our team has discussions underway regarding pathways to enter the Chinese market and realise the value of these opportunities."*

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating	Mr Brian Leedman
CEO and Managing Director	Executive Director, Corporate Affairs
+61 430 180 659	+61 412 281 780
tony@resapphealth.com.au	brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.